Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.Ye Guo, Jin Li, Xu Zhu et al.|Journal of Clinical Oncology|2023Cited by 11
Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.Ye Guo, Jin Li, Chunwang Yuan et al.|Journal of Clinical Oncology|2021Cited by 10